Sundry Photography / Shutterstock.com
16 February 2021AmericasRory O'Neill
Amgen antibody patents ‘too broad’, says Fed Circuit
The US Court of Appeals for the Federal Circuit has invalidated two Amgen antibody patents, finding that their functional claims were too broad.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Biotechnology
1 April 2021 Amgen v Sanofi continues the Federal Circuit’s trend of undermining certain antibody claims, explains Benjamin Pelletier of Haynes and Boone.
Big Pharma
27 August 2019 Amgen has entered into an agreement with Celgene to acquire worldwide rights to Otezla, the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, for $13.4 billion.
Americas
7 September 2021 Amgen has settled its dispute with Pfizer subsidiary Hospira, which it had accused of infringing a patent covering its blockbuster cancer drug treatment Neupogen.
Editor's picks
Editor's picks
Biotechnology
1 April 2021 Amgen v Sanofi continues the Federal Circuit’s trend of undermining certain antibody claims, explains Benjamin Pelletier of Haynes and Boone.
Big Pharma
27 August 2019 Amgen has entered into an agreement with Celgene to acquire worldwide rights to Otezla, the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, for $13.4 billion.
Americas
7 September 2021 Amgen has settled its dispute with Pfizer subsidiary Hospira, which it had accused of infringing a patent covering its blockbuster cancer drug treatment Neupogen.
Biotechnology
1 April 2021 Amgen v Sanofi continues the Federal Circuit’s trend of undermining certain antibody claims, explains Benjamin Pelletier of Haynes and Boone.
Big Pharma
27 August 2019 Amgen has entered into an agreement with Celgene to acquire worldwide rights to Otezla, the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, for $13.4 billion.
Americas
7 September 2021 Amgen has settled its dispute with Pfizer subsidiary Hospira, which it had accused of infringing a patent covering its blockbuster cancer drug treatment Neupogen.